Lab21 to Market deCODE Tests for Assessing Risk of Common Diseases

Lab21 Limited has announced that it has entered into a partnership with deCODE genetics; to offer deCODE’s tests for predisposition to a growing number of common diseases.

The licence allows Lab21 to offer its clients in the UK and Ireland access to new tests for type 2 diabetes, myocardial infarction, atrial fibrillation, prostate cancer and glaucoma.

This agreement means Lab21 now has licences with three major genetic test providers; deCODE, Myriad and PGxHealth, and is currently the only service provider in Europe to offer such an extensive range.

deCODE, a biopharmaceutical company based in Reykjavik, Iceland, is widely regarded as being the global leader in the development of tests for validated genetic markers that confer risk of common diseases.

In addition, the license will allow Lab21 to offer a pipeline of new tests as they are developed by deCODE, including one for increased risk of oestrogen-positive breast cancer. All deCODE tests have been validated in thousands of patients and controls from multiple populations; have full regulatory approval; and will be handled through Lab21’s clinical service laboratory in Cambridge.